Ignite Creation Date:
2024-05-06 @ 9:25 AM
Last Modification Date:
2024-10-26 @ 12:14 PM
Study NCT ID:
NCT02978495
Status:
COMPLETED
Last Update Posted:
2022-12-28
First Post:
2016-11-24
Brief Title:
Neoadjuvant Carboplatin in Triple Negative Breast Cancer
Sponsor:
Barretos Cancer Hospital
Organization:
Barretos Cancer Hospital
Study Overview
Official Title:
Neoadjuvant Carboplatin in Triple Negative Breast Cancer - A Prospective Phase II Study NACATRINE Trial
Status:
COMPLETED
Status Verified Date:
2022-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Breast cancer is the most frequent neoplasm in women in Brazil and in the world and up to 15 of all cases diagnosed correspond to the triple negative subtype Triple negative breast cancer affects young women with germline mutations in BRCA 12 genes Giving the lack of target therapies to date there is no consensus regarding the most effective treatment for this subgroup of tumors Although evidence shows that triple negative breast cancer is highly sensitive to chemotherapy when compared to other breast tumors there is no evidence to support the hypothesis that patients with triple negative breast cancer and mutation in BRCA1 2 genes have higher chemosensitivity to neoadjuvant therapy The investigator proposes a prospective randomized open-label phase II study evaluating the rate of complete pathologic response disease-free survival overall survival and prognostic evaluation of BRCA1 2 mutation status in women with triple negative breast cancer submitted to sequential neoadjuvant chemotherapy based on anthracycline and taxane with or without carboplatin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None